Skip to main content
Top
Published in: Clinical and Translational Oncology 8/2017

01-08-2017 | Research Article

Fecal incontinence and radiation dose on anal sphincter in patients with locally advanced rectal cancer (LARC) treated with preoperative chemoradiotherapy: a retrospective, single-institutional study

Authors: F. Arias, C. Eito, G. Asín, I. Mora, K. Cambra, F. Mañeru, B. Ibáñez, L. Arbea, A. Viudez, I. Hernández, J. I. Arrarás, M. Errasti, M. Barrado, M. Campo, I. Visus, S. Flamarique, M. A. Ciga

Published in: Clinical and Translational Oncology | Issue 8/2017

Login to get access

Abstract

Background

The objective of the study is to determine the correlations among the variables of dose and the sphincter function (SF) in patients with locally advanced rectal cancer treated with preoperative capecitabine/radiotherapy followed by low anterior resection (LAR) + TME.

Methods

We retrospectively reviewed 92 consecutive patients with LARC treated at our center with LAR from 2006 and more than 2 years free from disease. We re-contoured the anal sphincters (AS) of patients with the help of the radiologist. SF was assessed with the Wexner scale (0–20 points, being punctuation inversely proportional to annal sphincter functionality). All questionnaires were filled out between January 2010 and December 2012. Dosimetric parameters that have been studied include V 20, V 30, V 40, V 50, mean dose (D mean), minimum dose (D min), D 90 (dose received by 90% of the sphincter) and D 98.

Statistical analysis

The correlations among the variables of dose and SF were studied by the Spearman correlation coefficient. Differences in SF relating to maximum doses to the sphincter were assessed by the Mann–Whitney test.

Results

Mean Wexner score was 5.5 points higher in those patients with V 20 > 0 compared to those for which V 20 = 0 (p = 0.008). In a multivariate regression model, results suggest that the effect of V 20 on poor anal sphincter control is independent of the effect of distance, with an adjusted OR of 3.42.

Conclusions

In order to improve the SF in rectal cancer treated with preoperative radiotherapy/capecitabine followed by conservative surgery, the maximum radiation dose to the AS should be limited, when possible, to <20 Gy.
Literature
1.
go back to reference U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2016. http://www.cdc.gov/uscs. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2016. http://​www.​cdc.​gov/​uscs.
2.
go back to reference Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRef Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRef
3.
go back to reference Wong RKS, Tandan V, De Silva S, Figueredo A. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochr Datab Syst Rev. 2007, Issue 2. Art. No.: CD002102. doi:10.1002/14651858.CD002102.pub2. Wong RKS, Tandan V, De Silva S, Figueredo A. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochr Datab Syst Rev. 2007, Issue 2. Art. No.: CD002102. doi:10.​1002/​14651858.​CD002102.​pub2.
4.
go back to reference Cedermark B, Johansson H, Rutqvist LE, Wilking N. The Stockholm I Trial of preoperative short term radiotherapy in operable rectal carcinoma. Cancer. 1995;75:2269–75.CrossRef Cedermark B, Johansson H, Rutqvist LE, Wilking N. The Stockholm I Trial of preoperative short term radiotherapy in operable rectal carcinoma. Cancer. 1995;75:2269–75.CrossRef
5.
go back to reference Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):690–2.CrossRef Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):690–2.CrossRef
6.
go back to reference Stockholm Colorectal Cancer Study Group & Cedermark. B. Ann Surg Oncol. 1996;3:423.CrossRef Stockholm Colorectal Cancer Study Group & Cedermark. B. Ann Surg Oncol. 1996;3:423.CrossRef
7.
go back to reference Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50.CrossRef Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50.CrossRef
8.
go back to reference Marijnen CAM, van de Velde CJH, Putter H, van den Brink M, Maas CP, Martijn H, et al. Impact of short-term preoperative radiotherapy on health related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005;23:1847–58.CrossRef Marijnen CAM, van de Velde CJH, Putter H, van den Brink M, Maas CP, Martijn H, et al. Impact of short-term preoperative radiotherapy on health related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005;23:1847–58.CrossRef
9.
go back to reference Stephens RJ, Thompson LC, Quirke P, Steele R, Grieve R, Couture J, et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients’ quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol. 2010;28:4233–9.CrossRef Stephens RJ, Thompson LC, Quirke P, Steele R, Grieve R, Couture J, et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients’ quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol. 2010;28:4233–9.CrossRef
10.
go back to reference Yen-TingChen T, Emmertsen KJ, Laurberg S. What are the best questionnaires to capture anorectal function after surgery in rectal cancer? Curr Colorectal Cancer Rep. 2015;11:37–43.CrossRef Yen-TingChen T, Emmertsen KJ, Laurberg S. What are the best questionnaires to capture anorectal function after surgery in rectal cancer? Curr Colorectal Cancer Rep. 2015;11:37–43.CrossRef
11.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRef
12.
go back to reference Jorge JMN, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993;36:77–97.CrossRef Jorge JMN, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993;36:77–97.CrossRef
13.
go back to reference Alsadius D, Hedelin M, Lundstedt D, Pettersson N, Wilderäng U, Steineck G. Mean absorbed dose to the anal-sphincter region and fecal leakage among irradiated prostate cancer survivors. Int J Radiat Oncol Biol Phys. 2012;84:181–5.CrossRef Alsadius D, Hedelin M, Lundstedt D, Pettersson N, Wilderäng U, Steineck G. Mean absorbed dose to the anal-sphincter region and fecal leakage among irradiated prostate cancer survivors. Int J Radiat Oncol Biol Phys. 2012;84:181–5.CrossRef
14.
go back to reference Dunberger G, Lind H, Steineck G, Waldenström AC, Nyberg T, Al-Abany M, et al. Self-reported symptoms of faecal incontinence among long-term gynaecological cancer survivors and population-based controls. Eur J Cancer. 2010;46(3):606–15.CrossRef Dunberger G, Lind H, Steineck G, Waldenström AC, Nyberg T, Al-Abany M, et al. Self-reported symptoms of faecal incontinence among long-term gynaecological cancer survivors and population-based controls. Eur J Cancer. 2010;46(3):606–15.CrossRef
15.
go back to reference Maeda Y, Parés D, Norton C, Vaizey CJ, Kamm MA. Does the St. Mark’s incontinence score reflect patients’ perceptions? A review of 390 patients. Dis Colon Rectum. 2008;51:436–42.CrossRef Maeda Y, Parés D, Norton C, Vaizey CJ, Kamm MA. Does the St. Mark’s incontinence score reflect patients’ perceptions? A review of 390 patients. Dis Colon Rectum. 2008;51:436–42.CrossRef
16.
go back to reference Alburquerque A. Endoanal ultrasonography in fecal incontinence: current and future perspectives. World J Gastrointest Endosc. 2015;7:575–81.CrossRef Alburquerque A. Endoanal ultrasonography in fecal incontinence: current and future perspectives. World J Gastrointest Endosc. 2015;7:575–81.CrossRef
17.
go back to reference Parangama C, Anu E, Sukria N. Endoanal ultrasound assessment of sphincter defects and thinning—correlation with anal manometry. Arab J Gastroenterol. 2014;15(1):27–31.CrossRef Parangama C, Anu E, Sukria N. Endoanal ultrasound assessment of sphincter defects and thinning—correlation with anal manometry. Arab J Gastroenterol. 2014;15(1):27–31.CrossRef
18.
go back to reference Kadoya N. Use of deformable image registration for radiotherapy applications. J Radiol Radiat Ther. 2014;2:1042. Kadoya N. Use of deformable image registration for radiotherapy applications. J Radiol Radiat Ther. 2014;2:1042.
19.
go back to reference Emmertsen KJ, Laurberg S, Rectal Cancer Function Study Group. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg. 2013;100(10):1377–87.CrossRef Emmertsen KJ, Laurberg S, Rectal Cancer Function Study Group. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg. 2013;100(10):1377–87.CrossRef
20.
go back to reference Engel J, Kerr J, Schlesinger-Raab A, Eckel R, Sauer H, Hölzel D. Quality of life in rectal cancer patients. A four-year prospective study. Ann Surg. 2003;238(2):203–13.PubMedPubMedCentral Engel J, Kerr J, Schlesinger-Raab A, Eckel R, Sauer H, Hölzel D. Quality of life in rectal cancer patients. A four-year prospective study. Ann Surg. 2003;238(2):203–13.PubMedPubMedCentral
21.
go back to reference Schaake W, van der Schaaf A, van Dijk L, Bongaerts A, van den Bergh A, Langendijk J. Normal tissue complication probability (NTCP) models for late rectal bleeding, stool frequency and fecal incontinence after radiotherapy in prostate cancer patients. Radiother and Oncol. 2016;119:381–7.CrossRef Schaake W, van der Schaaf A, van Dijk L, Bongaerts A, van den Bergh A, Langendijk J. Normal tissue complication probability (NTCP) models for late rectal bleeding, stool frequency and fecal incontinence after radiotherapy in prostate cancer patients. Radiother and Oncol. 2016;119:381–7.CrossRef
Metadata
Title
Fecal incontinence and radiation dose on anal sphincter in patients with locally advanced rectal cancer (LARC) treated with preoperative chemoradiotherapy: a retrospective, single-institutional study
Authors
F. Arias
C. Eito
G. Asín
I. Mora
K. Cambra
F. Mañeru
B. Ibáñez
L. Arbea
A. Viudez
I. Hernández
J. I. Arrarás
M. Errasti
M. Barrado
M. Campo
I. Visus
S. Flamarique
M. A. Ciga
Publication date
01-08-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 8/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1627-0

Other articles of this Issue 8/2017

Clinical and Translational Oncology 8/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine